PFS per IRF by number of cycles of brentuximab vedotin received in the ITT population
| . | Treatment cycles, n . | ||
|---|---|---|---|
| 1-5 (n = 19) . | 6-12 (n = 17) . | 13-16 (n = 28) . | |
| Median PFS, months | 3.8 | 15.4 | 21.6 |
| PFS for extended follow-up, %* | |||
| 12 mo | 27.3 | 58.8 | 96.0 |
| 18 mo | 18.2 | 32.7 | 57.3 |
| 24 mo | 18.2 | 26.1 | 46.9 |
| . | Treatment cycles, n . | ||
|---|---|---|---|
| 1-5 (n = 19) . | 6-12 (n = 17) . | 13-16 (n = 28) . | |
| Median PFS, months | 3.8 | 15.4 | 21.6 |
| PFS for extended follow-up, %* | |||
| 12 mo | 27.3 | 58.8 | 96.0 |
| 18 mo | 18.2 | 32.7 | 57.3 |
| 24 mo | 18.2 | 26.1 | 46.9 |
Kaplan-Meier estimates.